TUESDAY, Jan. 21, 2025 (HealthDay News) — Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia.  But these drugs also come with risks that shouldn’t be overlooked, researchers warn in a study publishedContinue Reading

TUESDAY, Jan. 21, 2025 (HealthDay News) — Black people with obesity are less likely to get weight-loss surgery than others. Black people are just as likely to discuss the procedure with their doctor — nearly 10%, compared with 9% of patients of other races, researchers said. But only about 8%Continue Reading

WEDNESDAY, Jan. 15, 2025 (HealthDay News) — Grabbing a quick snack might soon come with a little extra clarity. The U.S. Food and Drug Administration (FDA) has proposed a new rule requiring bold, easy-to-read nutrition labels on the front of food and beverage packages. These labels, which would highlight contentContinue Reading

The way obesity is diagnosed needs to become more sophisticated, an international commission has concluded. Using body-mass index (BMI) to tell who is overweight or obese is not reliable, and can result in misdiagnosis, the Commission on Clinical Obesity says in a new paper published today in The Lancet DiabetesContinue Reading

THURSDAY, Jan. 2, 2024 (HealthDay News) — Weight loss tops many folks’ list of New Years resolutions, and lots of people are turning to cutting-edge weight-loss drugs like Ozempic to help them drop excess pounds. These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways toContinue Reading

THURSDAY, Dec. 26, (2024 HealthDay News)  — The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes. Liraglutide, the generic for Victoza, is similar to semaglutide, the active ingredient inContinue Reading